Charles A. Signorino, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Charles A. Signorino, PhD


Charles A. Signorino, PhD is a Pharmtech editorial advisory board (EAB) member

Charles A. Signorino, PhD
CEO
Emerson Resources, Inc.

Charles A. Signorino is the chief executive officer of Emerson Resources, Inc. He is an adjunct professor of pharmaceutics at the University of the Sciences in Philadelphia, and he has held positions at CS Associates Inc., Colorcon Inc., Eastern College, and Arco Chemical. His areas of expertise are aqueous enteric and film coating technology, FDA-approved colors and applications, pharmaceutical excipients, and rapid sugar coating.

Signorino is a member of the American Association of Pharmaceutical Scientists (AAPS), the American Chemical Society (ACS), and is also a member of the editorial advisory board for American Pharmaceutical Review. He has authored numerous technical publications, and he has given numerous seminars for various industry and academic events.

Signorino holds a BS from Pennsylvania State University, an MS and PhD from the University of Pennsylvania and an MAR from Westminster Theological Seminary.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here